Current reports
6-K
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
27 Sep 24
6-K/A
Current report (foreign) (amended)
10 Sep 24
6-K
Report of Foreign Private Issuer
10 Sep 24
6-K
LakeShore Biopharma Announces Leadership Transitions
4 Sep 24
6-K
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
15 Aug 24
6-K
Report of Foreign Private Issuer
5 Jul 24
6-K
Report of Foreign Private Issuer
18 Jun 24
6-K
Report of Foreign Private Issuer
10 Jun 24
6-K
YS Biopharma Announces Name Change to LakeShore Biopharma
24 May 24
6-K
YS Biopharma Announces Results of Extraordinary General Meeting
21 May 24
Registration and prospectus
S-8
Registration of securities for employees
20 May 24
424B3
Prospectus supplement
8 May 24
POS AM
Prospectus update (post-effective amendment)
23 Jan 24
424B3
Prospectus supplement
31 Oct 23
424B3
Prospectus supplement
26 Sep 23
424B3
Prospectus supplement
25 Sep 23
424B3
Prospectus supplement
25 Sep 23
424B3
Prospectus supplement
15 Aug 23
POS AM
Prospectus update (post-effective amendment)
8 Aug 23
S-8
Registration of securities for employees
7 Jul 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
26 Jan 24
EFFECT
Notice of effectiveness
11 Aug 23
EFFECT
Notice of effectiveness
6 Jun 23
CORRESP
Correspondence with SEC
31 May 23
CORRESP
Correspondence with SEC
12 May 23
UPLOAD
Letter from SEC
26 Apr 23
CERT
Certification of approval for exchange listing
16 Mar 23
EFFECT
Notice of effectiveness
8 Feb 23
CORRESP
Correspondence with SEC
2 Feb 23
CORRESP
Correspondence with SEC
25 Jan 23